23andMe's Innovative Contributions to Immuno-oncology
23andMe Holding Co. (Nasdaq: ME), a prominent player in human genetics and biopharmaceutical innovation, is poised to share exciting developments regarding its clinical immuno-oncology programs, specifically 23ME-00610 and 23ME-01473, at the esteemed ESMO Congress 2024. This significant event will occur from September 13 to September 17 in Barcelona, showcasing the groundbreaking advancements 23andMe is making in cancer treatment.
Exploring New Clinical Data
The company plans to reveal crucial preliminary findings from the renal cancer and TMB-H/MSI-H cohorts in its Phase 1/2a clinical trial for 23ME-00610, which is a cutting-edge anti-CD200R1 antibody. Additionally, 23andMe will provide insights from analyses that evaluate CD200 as an exploratory tissue-based biomarker associated with the effectiveness of 23ME-00610.
Preclinical Findings and Ongoing Studies
Moreover, 23andMe intends to present preclinical data on 23ME-01473, an anti-ULBP6 monoclonal antibody currently in dose escalation studies that commenced in March 2024. These studies are focused on how 23ME-01473 can effectively target soluble ULBP6, a component that plays a role in creating an immunosuppressive environment within tumors.
Clinical Trial Highlights from ASCO
Delving into its recent trial outcomes, 23andMe showcased promising results at the American Society of Clinical Oncology (ASCO) meeting. The monotherapy with 23ME-00610 demonstrated a favorable safety profile, along with early indications of clinical benefits in cohorts facing advanced cancers. Among the notable outcomes was a confirmed partial response in a patient diagnosed with pancreatic neuroendocrine cancer.
Innovative Biomarker Research
The exploration of CD200 is particularly noteworthy, as findings suggest it could act as a potential tissue-based biomarker, thereby enhancing precision in cancer treatment. This represents a significant advancement toward personalized medicine strategies grounded in genetic and immunological evaluations.
Presentation Details at ESMO
Here are the essential details regarding the presentations scheduled for ESMO:
- Abstract: 1069TiP
Title: A Phase 1/2a Dose Escalation and Expansion Study of 23ME-01473, an anti-ULBP6/2/5 Antibody for Patients with Advanced Solid Malignancies
Session Type: Poster Session – Investigational Immunotherapy
Date and Time: September 14, 9:00-17:00 CEST - Abstract: 620P
Title: Efficacy, Safety and PKPD of 23ME-00610 in Patients with TMB-H and/or MSI-H Cancers: Results from an Expansion Cohort
Session Type: Poster Session – Developmental Therapeutics
Date and Time: September 14, 9:00-17:00 CEST - Abstract: 153P
Title: 23ME-01473 Restores Anti-Tumor NK Cell Function Through NKG2D and FcgRIIIa Activation
Session Type: Poster Session – Biomarkers and Translational Research
Date and Time: September 15, 9:00-17:00 CEST - Abstract: 1706P
Title: Efficacy, Safety and PKPD of 23ME-00610 in Patients with Advanced Clear-Cell Renal Cell Carcinoma
Session Type: Poster Session – Renal Cancer
Date and Time: September 15, 9:00-17:00 CEST - Abstract: 150P
Title: Phase 1/2a Trial of CD200R1 Inhibitor 23ME-00610; Exploratory Analyses of Biomarkers
Session Type: Poster Session – Biomarkers and Translational Research
Date and Time: September 15, 9:00-17:00 CEST
Understanding the Innovations
23ME-00610 is engineered to inhibit the interaction between CD200R1 and CD200, targeting the CD200–CD200R1 axis, which is a vital immunological checkpoint that regulates immune tolerance. By targeting this pathway, it may enhance the ability of immune cells to combat cancer more effectively.
In contrast, 23ME-01473 aims to restore anti-tumor immune responses through Natural Killer (NK) and T cells by targeting the ULBP6 ligands that cancer cells often shed to avoid detection. This mechanism bolsters the immune response against tumors, potentially transforming the field of cancer immunotherapy.
About 23andMe
23andMe is leading the way in integrating genetic data into healthcare solutions and developing biopharmaceutical products that promise a healthier future for everyone. They harness genetic insights gathered from millions of participants to investigate and validate potential treatments based on genetic predispositions.
Frequently Asked Questions
What new trials will 23andMe present at ESMO Congress 2024?
23andMe will present trials related to its anti-CD200R1 antibody, 23ME-00610, and the anti-ULBP6 monoclonal antibody, 23ME-01473.
What is 23ME-00610?
23ME-00610 is a first-in-class monoclonal antibody targeting CD200R1, aimed at enhancing immune responses against cancer.
What is the significance of CD200 in cancer treatment?
CD200 serves as an immunological checkpoint; blocking its pathway could restore immune function in cancer patients.
How does 23ME-01473 function?
23ME-01473 targets soluble ULBP6 to encourage NK and T cell recognition of cancer cells, restoring anti-tumor immunity.
What role does 23andMe's genetic database play?
The genetic database enables 23andMe to discover drug targets by correlating genetic variants with immune response and cancer risk.